J Robert McCorkle
Overview
Explore the profile of J Robert McCorkle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
McDowell Jr A, Hill K, McCorkle J, Gorski J, Zhang Y, Salahudeen A, et al.
Diagnostics (Basel)
. 2021 Mar;
11(3).
PMID: 33652561
Background: Ovarian cancer is the deadliest gynecologic malignancy despite current first-line treatment with a platinum and taxane doublet. Artesunate has broad antineoplastic properties but has not been investigated in combination...
12.
Neupane K, McCorkle J, Kopper T, Lakes J, Aryal S, Abdullah M, et al.
ACS Omega
. 2021 Feb;
6(5):3847-3857.
PMID: 33585763
Macrophages, one of the most important phagocytic cells of the immune system, are highly plastic and are known to exhibit diverse roles under different pathological conditions. The ability to repolarize...
13.
Schweer D, McCorkle J, Rohr J, Tsodikov O, Ueland F, Kolesar J
Biomedicines
. 2021 Jan;
9(1).
PMID: 33445667
Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and...
14.
Lopez-Lopez E, Autry R, Smith C, Yang W, Paugh S, Panetta J, et al.
J Clin Invest
. 2020 Nov;
130(12):6600-6615.
PMID: 33164984
BACKGROUNDInterpatient differences in the accumulation of methotrexate's active polyglutamylated metabolites (MTXPGs) in leukemia cells influence its antileukemic effects.METHODSTo identify genomic and epigenomic and patient variables determining the intracellular accumulation of...
15.
Autry R, Paugh S, Carter R, Shi L, Liu J, Ferguson D, et al.
Nat Cancer
. 2020 Sep;
1(3):329-344.
PMID: 32885175
Identification of genomic and epigenomic determinants of drug resistance provides important insights for improving cancer treatment. Using agnostic genome-wide interrogation of mRNA and miRNA expression, DNA methylation, SNPs, CNAs and...
16.
Burgess B, Anderson A, McCorkle J, Wu J, Ueland F, Kolesar J
Diagnostics (Basel)
. 2020 Feb;
10(2).
PMID: 32098452
Objective: Despite the promise of PARP inhibitors (PARPi) for treating mutated ovarian cancer (OC), drug resistance invariably develops. We hypothesized rationale drug combinations, targeting key molecules in DNA repair pathways...
17.
Snell A, Neupane K, McCorkle J, Fu X, Moonschi F, Caudill E, et al.
ACS Omega
. 2019 Aug;
4(7):12657-12664.
PMID: 31460386
Efficient delivery of therapeutics across the cell membrane to the interior of the cell remains a challenge both in vitro and in vivo. Here, we demonstrate that vesicles derived from...
18.
Paugh S, Bonten E, Savic D, Ramsey L, Thierfelder W, Gurung P, et al.
Nat Genet
. 2015 May;
47(6):607-14.
PMID: 25938942
Glucocorticoids are universally used in the treatment of acute lymphoblastic leukemia (ALL), and resistance to glucocorticoids in leukemia cells confers poor prognosis. To elucidate mechanisms of glucocorticoid resistance, we determined...